Calidi Biotherapeutics, Inc. (CLDI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Calidi Biotherapeutics, Inc. (CLDI) trades at $0.0995 with AI Score 26/100 (Grade F). Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cell-based delivery platforms for oncolytic viruses. Sector: Healthcare.
Price as of Jul 21, 2026 · Last analyzed: May 4, 2026Analyst Coverage for CLDI: CLDI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CLDI against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CLDI: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Calidi Biotherapeutics, Inc. (CLDI) Healthcare & Pipeline Overview
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company pioneering cell-based delivery platforms for oncolytic viruses, targeting high-grade gliomas and metastatic solid tumors. Their innovative approach seeks to improve treatment efficacy and patient safety in the competitive biotechnology landscape, addressing unmet needs in cancer therapy.
What Is the Investment Thesis for CLDI?
Calidi Biotherapeutics presents a compelling investment thesis centered on its innovative cell-based delivery platforms for oncolytic viruses. The company's approach aims to enhance the efficacy and safety of cancer treatments, addressing a significant unmet need in the oncology space. With a pipeline including NeuroNova for high-grade gliomas and SuperNova for metastatic solid tumors, Calidi is targeting challenging cancer indications with significant market potential. Key value drivers include successful clinical trial outcomes, strategic partnerships, and regulatory approvals. The company's focus on allogeneic stem cells offers potential advantages in terms of scalability and cost-effectiveness. A beta of 1.42 indicates higher volatility compared to the market. Upcoming clinical trial data for NeuroNova and SuperNova will be critical catalysts. Potential risks include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The company's market capitalization is $0.00B as of 2026-05-04.
Based on FMP financials and quantitative analysis
CLDI Key Highlights
- Calidi Biotherapeutics is a clinical-stage immuno-oncology company focused on developing cell-based delivery platforms for oncolytic viruses.
- The company's lead product candidates, NeuroNova and SuperNova, target high-grade gliomas and advanced metastatic solid tumors, respectively.
- Calidi's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses, potentially enhancing efficacy and improving patient safety.
- The company was founded in 2014 and is based in San Diego, California, indicating a relatively young but focused organization.
- Calidi's approach aims to overcome the limitations of traditional cancer therapies by providing more effective and targeted treatment options.
Who Are CLDI's Competitors?
CLDI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CGON CG Oncology Inc | $70.19 | -2.31% | $6.19B | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | -9.09% | $7.95M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.49 | +6.41% | $235M | 76 |
| NAGE Niagen Bioscience Inc | $3.49 | +3.56% | $278M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CLDI's Key Strengths?
- Innovative cell-based delivery platforms.
- Targeting unmet needs in cancer treatment.
- Experienced management team.
- Promising early clinical data.
What Are CLDI's Weaknesses?
- Clinical-stage company with no approved products.
- Limited financial resources.
- High risk of clinical trial failures.
- Dependence on key personnel.
What Could Drive CLDI Stock Higher?
- Clinical trial data readouts for NeuroNova in high-grade gliomas.
- Clinical trial data readouts for SuperNova in advanced metastatic solid tumors.
- Potential for strategic partnerships and collaborations.
- Advancement of pipeline through clinical development.
What Are the Key Risks for CLDI?
- Financial-distress signal — its Altman Z-Score of -27.23 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory hurdles and delays.
- Competition from established pharmaceutical companies.
- Limited financial resources.
- Dependence on key personnel.
What Are the Growth Opportunities for CLDI?
- Expansion into New Therapeutic Areas: Calidi Biotherapeutics has the opportunity to expand its cell-based delivery platform to target other cancer types beyond high-grade gliomas and metastatic solid tumors. By exploring new oncology indications, such as lung cancer, breast cancer, and melanoma, Calidi can significantly increase its market potential. This expansion could involve developing new oncolytic virus payloads or modifying its stem cell delivery platform to target specific tumor microenvironments. The market for targeted cancer therapies is substantial, with each new indication representing a multi-billion dollar opportunity. Timeline: 2-3 years for preclinical development and initiation of clinical trials.
- Strategic Partnerships and Collaborations: Calidi can accelerate its growth by forming strategic partnerships with pharmaceutical companies, research institutions, and other biotechnology firms. These collaborations can provide access to funding, expertise, and resources, enabling Calidi to advance its pipeline and expand its commercial reach. Partnerships could involve co-development agreements, licensing deals, or joint ventures. The value of such partnerships can range from millions to hundreds of millions of dollars, depending on the scope and potential of the collaboration. Timeline: Ongoing, with potential for new partnerships to be announced within the next year.
- Advancement of Clinical Trials: The successful advancement of NeuroNova and SuperNova through clinical trials is critical for Calidi's growth. Positive clinical trial data will validate the efficacy and safety of its cell-based delivery platform, attracting further investment and paving the way for regulatory approvals. Each phase of clinical development represents a significant milestone, with the potential to increase the company's valuation. The market for effective cancer therapies is substantial, with premium pricing for innovative treatments. Timeline: Ongoing, with key clinical trial readouts expected in the next 12-24 months.
- Securing Regulatory Approvals: Obtaining regulatory approvals from agencies such as the FDA and EMA is essential for commercializing Calidi's products. Regulatory approvals will allow Calidi to market and sell its therapies to patients, generating revenue and establishing a sustainable business. The regulatory pathway for cancer therapies is rigorous, requiring extensive clinical data and manufacturing controls. The market exclusivity granted by regulatory approvals provides a significant competitive advantage. Timeline: 3-5 years, depending on clinical trial outcomes and regulatory review processes.
- Expansion of Manufacturing Capabilities: As Calidi's pipeline advances, the company will need to expand its manufacturing capabilities to meet the anticipated demand for its products. This expansion may involve building new manufacturing facilities or outsourcing production to contract manufacturing organizations (CMOs). Scalable and cost-effective manufacturing processes are essential for ensuring the commercial viability of Calidi's therapies. The market for cell-based therapies is growing rapidly, with increasing demand for high-quality manufacturing services. Timeline: 2-3 years, with ongoing investments in manufacturing infrastructure.
What Opportunities Does CLDI Have?
- Expansion into new therapeutic areas.
- Strategic partnerships and collaborations.
- Securing regulatory approvals.
- Advancement of clinical trials.
What Threats Does CLDI Face?
- Competition from established pharmaceutical companies.
- Regulatory hurdles.
- Clinical trial failures.
- Economic downturn.
What Are CLDI's Competitive Advantages?
- Proprietary cell-based delivery platforms for oncolytic viruses.
- Strong intellectual property portfolio protecting its technology.
- Clinical-stage pipeline with promising early results.
- Experienced management team with expertise in immuno-oncology.
What Does CLDI Do?
Founded in 2014 and based in San Diego, California, Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company dedicated to developing innovative immunotherapies for cancer treatment. The company focuses on advancing a potent allogeneic stem cell platform capable of delivering anti-tumor payloads to various oncology indications, including high-grade gliomas and solid tumors. Calidi's core technology revolves around cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses, ultimately enhancing efficacy and improving patient safety. Their pipeline includes NeuroNova, which utilizes allogeneic neural stem cells loaded with an oncolytic adenovirus for treating high-grade gliomas, and SuperNova, which employs allogeneic adipose-derived mesenchymal stem cells loaded with the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. By leveraging these innovative platforms, Calidi aims to overcome the limitations of traditional cancer therapies and provide more effective and targeted treatment options for patients with challenging cancers. The company's focus on allogeneic stem cells allows for off-the-shelf availability, potentially reducing manufacturing complexities and treatment timelines compared to autologous cell therapies. Calidi's strategic approach positions it as a key player in the evolving field of immuno-oncology, with a commitment to developing next-generation cancer therapies.
What Products and Services Does CLDI Offer?
- Develop immunotherapies for cancer treatment.
- Advance allogeneic stem cell platforms for delivering anti-tumor payloads.
- Design cell-based delivery platforms to protect and amplify oncolytic viruses.
- Develop NeuroNova for the treatment of high-grade gliomas.
- Develop SuperNova for the treatment of advanced metastatic solid tumors.
- Focus on enhancing efficacy and improving patient safety in cancer treatment.
How Does CLDI Make Money?
- Develop and commercialize cell-based immunotherapies for cancer.
- Generate revenue through sales of approved therapies.
- Establish strategic partnerships and collaborations for co-development and licensing.
- Secure funding through venture capital, grants, and public offerings.
What Industry Does CLDI Operate In?
Calidi Biotherapeutics operates within the rapidly evolving immuno-oncology market, a segment of the biotechnology industry focused on harnessing the body's immune system to fight cancer. The market is characterized by intense competition, with numerous companies developing novel therapies, including checkpoint inhibitors, CAR-T cell therapies, and oncolytic viruses. Calidi's unique approach, utilizing cell-based delivery platforms for oncolytic viruses, positions it as a potential disruptor in the field. Calidi's success will depend on its ability to demonstrate clinical efficacy and safety, secure regulatory approvals, and establish strategic partnerships.
Who Are CLDI's Key Customers?
- Patients with high-grade gliomas.
- Patients with advanced metastatic solid tumors.
- Hospitals and cancer treatment centers.
- Oncologists and other healthcare professionals.
CLDI Valuation & Market Position
Relative to its peer group, CLDI's quantitative score of 26/100 is below the peer average of 74/100.
F-Score 1/9Financial Health
Calidi Biotherapeutics, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -27.23 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Calidi Biotherapeutics, Inc. revenue of about $0 for fiscal 2026, with EPS near $-5.52.
CLDI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its potential.
- Community sentiment has shown increasing optimism, with discussions highlighting innovative therapies that could position Calidi favorably in the biotech sector.
- Positive developments in clinical trials reported in the last month have sparked interest and enthusiasm among investors.
- The overall trend in the biopharmaceutical market is leaning towards innovation, which could benefit companies like Calidi that are focused on unique treatment solutions.
Bear Case
- Concerns over the pace of clinical trial results may be dampening enthusiasm, as investors are wary of potential delays impacting future growth.
- Social sentiment has also revealed skepticism about the company's ability to compete with larger, established players in the biotech field.
- Recent market volatility has led to cautiousness among investors, causing some to reevaluate their positions in smaller biotech firms like Calidi.
- The lack of substantial revenue generation remains a critical concern, leading to doubts about the company's short-term financial health and sustainability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
CLDI Latest News
-
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga · Apr 28, 2026
CLDI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CLDI.
Price Targets
Wall Street price target analysis for CLDI.
CLDI MoonshotScore
What does this score mean?
The MoonshotScore rates CLDI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Eric E. Poma
CEO
Eric E. Poma serves as the Chief Executive Officer of Calidi Biotherapeutics, Inc. His background encompasses extensive experience in the biotechnology and pharmaceutical industries, with a focus on oncology and immunotherapy. Poma has held leadership positions in various companies, contributing to the development and commercialization of innovative therapies. His expertise spans strategic planning, business development, and clinical operations. Poma's educational background includes advanced degrees in science and business, providing him with a strong foundation for leading a clinical-stage biotechnology company.
Track Record: Under Eric E. Poma's leadership, Calidi Biotherapeutics has advanced its pipeline of cell-based immunotherapies, including NeuroNova and SuperNova, through clinical trials. He has overseen strategic partnerships and collaborations to accelerate the development and commercialization of the company's products. Poma has also been instrumental in securing funding to support Calidi's research and development efforts. His leadership has focused on building a strong team and fostering a culture of innovation.
Common Questions About CLDI (Healthcare)
What does the AI Score mean for CLDI?
CLDI holds an AI Score of 26/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing innovative cell-based delivery platforms for oncolytic viruses. Their approach aims to enhance …
What does Calidi Biotherapeutics, Inc. do?
Calidi Biotherapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing cell-based delivery platforms for oncolytic viruses. The company engineers allogeneic stem cells to carry anti-tumor payloads directly to tumors, enhancing the efficacy and safety of cancer treatments. Their lead product candidates, NeuroNova and SuperNova, target high-grade gliomas and advanced metastatic solid tumors, respectively.
What do analysts say about CLDI stock?
As of 2026-05-04, there is limited analyst coverage available for Calidi Biotherapeutics, Inc. given its market capitalization of $0.00B and clinical-stage status. Key valuation metrics are still developing as the company progresses through clinical trials. Growth considerations center on the successful advancement of NeuroNova and SuperNova through clinical development and potential regulatory approvals. Investors should closely monitor clinical trial data and strategic partnerships to assess the company's potential.
What are the main risks for CLDI?
The main risks for Calidi Biotherapeutics, Inc. include the inherent uncertainties of clinical-stage drug development, such as the potential for clinical trial failures and regulatory hurdles. Competition from established pharmaceutical companies and other biotechnology firms also poses a significant risk. Additionally, the company's limited financial resources and dependence on key personnel could impact its ability to execute its business plan.
What are the key factors to evaluate for CLDI?
Calidi Biotherapeutics, Inc. (CLDI) holds an AI score of 26/100 (low). Not financial advice.
How frequently does CLDI data refresh on this page?
CLDI's price was last updated on Jul 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven CLDI's recent stock price performance?
Calidi Biotherapeutics, Inc. (CLDI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative cell-based delivery platforms. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLDI overvalued or undervalued right now?
Calidi Biotherapeutics, Inc. (CLDI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research CLDI before investing?
Before investing in Calidi Biotherapeutics, Inc. (CLDI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available company data and may be subject to change.
- Analyst opinions and financial metrics are limited due to the company's clinical-stage status.